Thr309
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr309  -  CABLES1 (human)

Site Information
APLRRCRtLsGsPRP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4270180

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 ) , mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
adrenal cancer ( 1 ) , pheochromocytoma ( 1 ) , gastric cancer ( 2 , 3 , 4 , 5 ) , gastric carcinoma ( 2 , 3 , 4 , 5 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:
COS7 (fibroblast) ( 1 ) , HEK293T (epithelial) ( 1 ) , HeLa S3 (cervical) ( 10 ) , Jurkat (T lymphocyte) ( 6 , 7 ) , MKN-45 (gastric) ( 2 , 3 , 4 , 5 , 8 , 9 ) , PC-12 (chromaffin) ( 1 )

Upstream Regulation
Putative in vivo kinases:
Akt1 (human) ( 1 )
Kinases, in vitro:
Akt1 (human) ( 1 )
Treatments:
Akt-I-1,2 ( 1 ) , IGF-1 ( 1 ) , INK-128 ( 1 ) , LY294002 ( 1 ) , SB216763 ( 1 )

Downstream Regulation
Effects of modification on CABLES1:
enzymatic activity, induced ( 1 ) , molecular association, regulation ( 1 ) , phosphorylation ( 1 )
Effects of modification on biological processes:
apoptosis, inhibited ( 1 ) , carcinogenesis, induced ( 1 ) , transcription, altered ( 1 )
Induce interaction with:
14-3-3 gamma (human) ( 1 )
Inhibit interaction with:
CDK2 (human) ( 1 )

References 

1

Shi Z, et al. (2015) Cables1 complex couples survival signaling to the cell death machinery. Cancer Res 75, 147-58
25361894   Curated Info

2

Mulhern D (2012) CST Curation Set: 13405; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

3

Moritz A (2011) CST Curation Set: 12042; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

4

Moritz A (2011) CST Curation Set: 12047; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

5

Moritz A (2011) CST Curation Set: 11934; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

6

Guo A (2011) CST Curation Set: 11890; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

7

Guo A (2011) CST Curation Set: 11892; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

8

Moritz A (2008) CST Curation Set: 5380; Year: 2008; Biosample/Treatment: cell line, MKN-45/wortmannin; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

9

Moritz A (2008) CST Curation Set: 5010; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

10

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.